Editas Medicine to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Editas Medicine (Nasdaq: EDIT), a leading gene editing company, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's President and CEO, Gilmore O'Neill, will deliver a presentation on Wednesday, January 15, 2025, at 11:15 a.m. PT / 2:15 p.m. ET in San Francisco, CA.
Interested parties can access a live webcast of the presentation through the "Investors" section of the Editas Medicine website. The presentation recording will remain available on the company's website for approximately 30 days after the event.
Editas Medicine (Nasdaq: EDIT), una delle principali aziende di editing genetico, ha annunciato la sua partecipazione alla 43ª Conferenza Annuale sulla Sanità J.P. Morgan. Il Presidente e CEO dell'azienda, Gilmore O'Neill, presenterà il suo intervento mercoledì 15 gennaio 2025, alle 11:15 PT / 14:15 ET a San Francisco, CA.
Le parti interessate possono accedere a una diretta streaming della presentazione attraverso la sezione
Editas Medicine (Nasdaq: EDIT), una de las principales empresas de edición genética, ha anunciado su participación en la 43ª Conferencia Anual sobre Salud de J.P. Morgan. El Presidente y CEO de la compañía, Gilmore O'Neill, realizará una presentación el miércoles 15 de enero de 2025, a las 11:15 a.m. PT / 2:15 p.m. ET en San Francisco, CA.
Las partes interesadas pueden acceder a una transmisión en vivo de la presentación a través de la sección de
Editas Medicine (Nasdaq: EDIT), 선도적인 유전자 편집 회사,가 제43회 JP 모건 헬스케어 컨퍼런스에 참여할 것이라고 발표했습니다. 회사의 회장이자 CEO인 Gilmore O'Neill은 2025년 1월 15일 수요일, 오전 11시 15분 PT / 오후 2시 15분 ET에 샌프란시스코, CA에서 발표를 할 예정입니다.
관심 있는 당사자는 Editas Medicine 웹사이트의
Editas Medicine (Nasdaq: EDIT), une entreprise leader dans l'édition génétique, a annoncé sa participation à la 43e Conférence Annuelle sur la Santé J.P. Morgan. Le Président et CEO de la société, Gilmore O'Neill, fera une présentation le mercredi 15 janvier 2025, à 11h15 PT / 14h15 ET à San Francisco, CA.
Les parties intéressées peuvent accéder à une diffusion en direct de la présentation via la section
Editas Medicine (Nasdaq: EDIT), ein führendes Unternehmen im Bereich der Genom-Editierung, hat seine Teilnahme an der 43. J.P. Morgan Healthcare Conference angekündigt. Der Präsident und CEO des Unternehmens, Gilmore O'Neill, wird am Mittwoch, den 15. Januar 2025, um 11:15 Uhr PT / 14:15 Uhr ET in San Francisco, CA, eine Präsentation halten.
Interessierte Parteien können die Live-Übertragung der Präsentation über den Bereich
- None.
- None.
CAMBRIDGE, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading gene editing company, today announced that the Company’s President and CEO Gilmore O’Neill, M.B., M.M.Sc., will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, 11:15 a.m. PT / 2:15 p.m. ET in San Francisco, CA.
A live webcast of the presentation will be available on the “Investors” section of the Editas Medicine website at www.editasmedicine.com. An archived replay will be available on the website for approximately 30 days following the presentation.
About Editas Medicine
As a leading gene editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas12a and CRISPR/Cas9 genome editing systems into a robust pipeline of in vivo medicines for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision in vivo gene editing medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute’s Cas12a patent estate and Broad Institute and Harvard University’s Cas9 patent estates for human medicines. For the latest information and scientific presentations, please visit www.editasmedicine.com.
FAQ
When is Editas Medicine (EDIT) presenting at the 2025 J.P. Morgan Healthcare Conference?
How can investors watch Editas Medicine's (EDIT) J.P. Morgan Healthcare Conference presentation?
How long will Editas Medicine's (EDIT) 2025 J.P. Morgan presentation be available for replay?
Who will represent Editas Medicine (EDIT) at the 2025 J.P. Morgan Healthcare Conference?
